inVentiv Health Clinical Appoints Lynn Okamoto Executive Vice President, Late-Stage Business Unit - Tucson News Now

inVentiv Health Clinical Appoints Lynn Okamoto Executive Vice President, Late-Stage Business Unit

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE inVentiv Health Clinical

Respected Research Scientist and Healthcare Analytics Expert to Lead Late-Stage Clinical Business

PRINCETON, N.J., Feb. 4, 2014 /PRNewswire/ -- inVentiv Health Clinical, a leading global supplier of drug development services, today announced that Lynn Okamoto, Pharm.D., will be joining the company as Executive Vice President of the Late Stage Business Unit effective March 3.

A skillful global manager and an expert in health outcomes research, Okamoto joins inVentiv Health after more than 20 years in the healthcare industry.  She most recently served as Senior Vice President and Senior Research Scientist of Health Economics & Epidemiology at Evidera, and previously led the Intelligent Health Repository at NDC Health. In addition to her demonstrated skill in building high-performance global teams, she also has a high degree of expertise in healthcare analytics and health outcomes research.

As healthcare systems throughout the world are challenged by spiraling healthcare costs, payers/health authorities, physicians and other healthcare decision makers are reviewing and in some instances requiring real-word evidence to support a product's value in clinical practice.

"inVentiv Health was built for this new marketplace, with the broadest range of convergent services in the industry," said Raymond Hill, President inVentiv Health Clinical.  "Our Late Stage Clinical group works seamlessly with inVentiv experts in study design and implementation, market access, reimbursement, stakeholder relations and scientific communications to anticipate the questions that will be asked in the marketplace and assure our clients are armed with effective answers." 

inVentiv Health understands how access, pricing and reimbursement all are tethered to outcomes and provides a full range of services including:

  • insightful design to registries and post approval studies
  • maximum participation from healthcare professionals, from planning to study outcomes
  • real-world evidence that can be pulled through to address market and customer needs
  • internal communications to support the cross-functional team.

With 12,000 employees worldwide, inVentiv boasts deep experience across all major therapeutic categories, one of the world's top CROs, the world's second largest communications network and unparalleled commercialization expertise that includes the largest sales and marketing forces in the United States.

About inVentiv Health Clinical
inVentiv Health Clinical is a leading provider of global drug development services to pharmaceutical, biotechnology, generic drug, and medical device companies, offering  therapeutically specialized capabilities for Phase I-IV clinical development, bioanalytical  services, and strategic resourcing from a single clinical professional to an entire functional  team. With 6,500 passionate employees operating in 70 countries, inVentiv Health Clinical works to accelerate high quality drug development programs of all sizes around the world.
http://www.inventivhealthclinical.com  

Contact:
Andy Malavsky
inVentiv Health Clinical
+1 609 580 8319
Andy.Malavsky@inventivhealth.com

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow